ALFA Filings
Every announcement, straight from the exchange
Every Dr. Lal Pathlabs merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Dr. Lal PathLabs' subsidiary, Dr Lal PathLabs FZCO, has incorporated a new step-down subsidiary, Dr Lal PathLabs Indomed LLC, in Tashkent, Uzbekistan, acquiring a 70% stake.
Dr. Lal Path Labs' subsidiary will acquire an 80% stake in Sunshine Healthcare Limited, Ghana. The transaction is valued at ₹38.0 Crore.
Dr. Lal Path Labs' subsidiary, Dr. Lal Ventures, is acquiring a 30% stake in Neuome Technologies for ₹3.5 Crore. This provides access to innovative bio-banking solutions.
Dr. Lal PathLabs incorporated a new wholly owned subsidiary in Dubai for ₹49.75 Crore. The entity will focus on international diagnostic service expansions and strategic investments.
Dr. Lal PathLabs Ltd incorporated a wholly owned subsidiary in Dubai named DR LAL PATHLABS FZCO. This subsidiary will focus on diagnostics and allied activities, including potential acquisitions and joint ventures.
Dr. Lal Path Labs Ltd. is incorporating a new wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO. The subsidiary will focus on diagnostic services and allied activities, including potential acquisitions and joint ventures in the region. The investment will be made at face value subject to regulatory approvals.